title: Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.
abstract: High levels of insulin-like growth factor (IGF)-I are reported to be associated with an increased risk of prostate cancer. On the other hand, the insulin-like growth factor binding protein-3 (IGFBP-3) may decrease the risk. We therefore investigated the influence of serum IGF-I and IGFBP-3 on prostate cancer risk in a case-control study nested within a large-scale cohort in Japan (the Japan Collaborative Cohort Study). Information on lifestyle and sera of the subjects were collected in 1988-90. Serum IGF-I, IGF-II and IGFBP-3 were measured in sera stored at -80 degrees C by immuno-radiometric assay. In 13,508 male subjects of the cohort who donated sera, 40 cases and 120 controls (1:3 matched with age and survey area) were identified. Ages of the cases ranged from 59 to 79 years, with a mean of 69.8. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for the highest and middle tertiles compared with the lowest in controls using a conditional logistic model. Non-adjusted ORs for the highest tertiles were 0.99 (95% CI, 0.34-2.91) for IGF-I (trend-P = 0.60), 1.91 (95% CI, 0.68-5.38) for IGFBP-3 (trend-P = 0.23), 1.73 (95% CI, 0.69-3.47) for IGF-II (trend-P = 0.23), and 0.67 (95% CI, 0.26-1.76) for the IGF-I/IGBP-3 ratio (trend-P = 0.83). Serum levels of IGF-I, IGF-II, IGFBP-3, or IGF-I/IGFBP-3 ratio were thus not thought to be associated with risk of prostate cancer.
authors.affiliation: Department of Urology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Japan. kmikami@koto.kpu-m.ac.jp
authors.forename: Kazuya
authors.initials: K
authors.lastname: Mikami
authors.forename: Kotaro
authors.initials: K
authors.lastname: Ozasa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nakao
authors.forename: Tsuneharu
authors.initials: T
authors.lastname: Miki
authors.forename: Kyohei
authors.initials: K
authors.lastname: Hayashi
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Mori
authors.forename: Fumio
authors.initials: F
authors.lastname: Sakauchi
authors.forename: Masakazu
authors.initials: M
authors.lastname: Washio
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Kubo
authors.forename: Koji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Kenji
authors.initials: K
authors.lastname: Wakai
authors.forename: Kei
authors.initials: K
authors.lastname: Nakachi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tajima
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Ito
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Inaba
authors.forename: Akiko
authors.initials: A
authors.lastname: Tamakoshi
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism*; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000453:epidemiology / Q000401:mortality*; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D015415:Biomarkers; D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II